Divis Labs

India's CRDMO sector growth rebounded to 19% YoY in Q1FY27 versus just 9% YoY in the March 2026 quarter, marking the highest growth level since the December 2024 quarter, notes Jefferies.

Chandan Taparia of Motilal Oswal Financial Services has recommended three stocks to buy today: Divi's Laboratories, MCX, and Eternal.

The brokerage said Divis Laboratories is entering a stronger growth phase, supported by a robust H2FY26 pipeline and visibility for scale-up over the next two years.

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

Leading the list is GNG Electronics (Target: ₹482 | Upside: 52%), named by Nirmal Bang, which expects robust growth as the company benefits from the govt's 'Make in India' thrust on electronics mfg.

Divi's Laboratories share price rose after the company announced that it has inked a long-term manufacturing and supply agreement with a global pharmaceutical company.

Divi's posted a 12 per cent growth in revenues over the year-ago quarter. Although revenue growth has moderated after four consecutive quarters of top line growth in the 18-25 per cent range

Divi's Labs share price jumped 5 per cent after posting healthy Q4 results and announcing 1,500 per cent dividend

Analysts believe that pharma shares continue to see buying interest, given the inelastic demand for medicines; tariffs, if any could have minimal impact on the industry.

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

Divi's Laboratories share price surged 5.36 per cent at Rs 6,205 per share on the BSE in the intraday trade of Tuesday. This came after the pharma company delivered robust third quarter results

Divi's Laboratories share price slipped 4.60 per cent at Rs 5,881.15 a piece on the BSE in Monday's intraday trade after the pharmaceutical company's consolidated net profit for the third quarter

Stocks to watch on February 3, 2025: GR Infra saw a 7.8 per cent increase in net profit in Q3, which stood at Rs 261.7 crore. However, revenue fell by 20.6 per cent to Rs 1,694.5 crore

The markets experienced a volatile session and ended nearly flat, taking a breather after three consecutive days of gains

Shares of Divis's Laboratories scaled up to 3.4 per cent at Rs 6145.60 per share on the BSE after beating street estimates in its second quarter earnings for the financial year 2024-25 (Q2FY25)

At 6:35 AM, GIFT Nifty Futures were down 82 points at 24,136, signalling a potential negative start

Brokerages expect Divis Labs to report a robust quarter on a year-on-year basis and sequentially

Individually, shares of Laurus Labs rose up to 5.55 per cent at Rs 517.90 per share, Akums Drugs and Pharmaceuticals shares locked in 5 per cent upper circuit at Rs 910.55 a piece

Shares of Divi's Laboratories surged up to 5 per cent at Rs 4960 per share on the BSE in Wednesday's intraday deals